Beschreibung
There is a lot of works done for targeting drug as nanoparticles for the treatment of cancer. But with this work I am anticipating a future scope of nanomedicines for cancer therapy followed by targeting them to lymphatic system. Imatinib mesylate is a drug I selected for this study and the result was shown that this type of therapy is very much effective for lymphoma. SLN can easily pass through the lymphatic system during systemic circulation, and this passive targeting enables the drug to be targeted to the lymphatic system.
Autorenporträt
Vivek R., working as assistant professor in KVM college of pharmacy, Cherthala, Aleppey district, Kerala. His educational qualification is M Pharm, PGDBA. M Pharm from M G university, Kerala and PGDBA from Sikkim Manipal University. He is very much interested in research area of nano-particles and its targeting.
Herstellerkennzeichnung:
BoD - Books on Demand
In de Tarpen 42
22848 Norderstedt
DE
E-Mail: info@bod.de
